CandlesenseCandlesense
SNYClinical Trials•globenewswire•

Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sentiment:Positive (70)

Summary

(NASDAQ:SNY) Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 11, 2025 by globenewswire

← Back to SNY News
    Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration | SNY Stock News | Candlesense